as 12-18-2024 1:38pm EST
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
Founded: | 1984 | Country: | United States |
Employees: | N/A | City: | NASHUA |
Market Cap: | 40.8M | IPO Year: | 1986 |
Target Price: | N/A | AVG Volume (30 days): | 340.6K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.10 | EPS Growth: | N/A |
52 Week Low/High: | $1.18 - $2.65 | Next Earning Date: | 11-13-2024 |
Revenue: | $18,940,000 | Revenue Growth: | 10.03% |
Revenue Growth (this year): | 10.15% | Revenue Growth (next year): | 3.75% |
ICAD Breaking Stock News: Dive into ICAD Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
GlobeNewswire
14 days ago
Simply Wall St.
15 days ago
GlobeNewswire
22 days ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
Thomson Reuters StreetEvents
a month ago
Associated Press Finance
a month ago
The information presented on this page, "ICAD iCAD Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.